Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future
Cancer J
.
2021 Mar-Apr;27(2):90-91.
doi: 10.1097/PPO.0000000000000518.
Authors
Eric L Smith
1
,
Renier J Brentjens
2
Affiliations
1
From the Dana-Farber Cancer Institute, Boston, MA.
2
Memorial Sloan Kettering Cancer Center, NY.
PMID:
33750066
PMCID:
PMC8285986
DOI:
10.1097/PPO.0000000000000518
No abstract available
Publication types
Editorial
MeSH terms
Humans
Immunotherapy, Adoptive*
Neoplasms* / therapy
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen* / genetics
Substances
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
Grants and funding
K08 CA241400/CA/NCI NIH HHS/United States
P30 CA006516/CA/NCI NIH HHS/United States
R01 CA138738/CA/NCI NIH HHS/United States